Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly

Pasireotide long-acting release is effective in achieving bioche mical control and reducing tumour volume in patients with acromegaly inadequately controll ed by first-line therapy. As part of a long-term, real-world study at our centre, 20 of 50 patients receiving pasireotide benefited from a reduc...

Full description

Bibliographic Details
Published in:	Endocrine Connections
Main Authors:	Nelma Veronica Marques, Luiz Eduardo Armondi Wildemberg, Monica R Gadelha
Format:	Article
Language:	English
Published:	Bioscientifica 2023-09-01
Subjects:	acromegaly pasireotide long-term hyperglycaemia dose reduction
Online Access:	https://ec.bioscientifica.com/view/journals/ec/12/10/EC-23-0155.xml

Similar Items

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
by: Soraya Puglisi, et al.
Published: (2020-02-01)

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
by: Sylvère Störmann, et al.
Published: (2024-02-01)

Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)

Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review
by: De Fano M, et al.
Published: (2024-07-01)

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly
by: Jan-Shun Chang, et al.
Published: (2016-06-01)

Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
by: Przemysław Witek, et al.
Published: (2024-12-01)

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study
by: Vittoria Favero, et al.
Published: (2024-02-01)

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences
by: Sabrina Chiloiro, et al.
Published: (2024-05-01)

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study
by: Ulla Feldt-Rasmussen, et al.
Published: (2024-03-01)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
by: Adrian F Daly, et al.
Published: (2019-04-01)

Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
by: Eva Venegas Moreno, et al.
Published: (2025-04-01)

New cross-roads for second line medical therapy in acromegaly
by: Adina Ghemigian, et al.
Published: (2018-03-01)

New opportunities for secondary drug therapy of acromegaly
by: V. S. Pronin, et al.
Published: (2020-05-01)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
by: Rosa Maria Paragliola, et al.
Published: (2018-03-01)

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
by: Yuki Taki, et al.
Published: (2025-04-01)

Case Report: Bilateral lens dislocation as an atypical presentation of acromegaly and review of the ocular effects of GH/IGF-1 excess
by: Laura Vitale, et al.
Published: (2025-10-01)

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance
by: Ioana Rada Popa Ilie, et al.
Published: (2024-12-01)

Pasireotide in the Personalized Treatment of Acromegaly
by: Manel Puig-Domingo, et al.
Published: (2021-03-01)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
by: Feun LG, et al.
Published: (2018-01-01)

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context
by: Thierry Brue, et al.
Published: (2021-10-01)

Pasireotide after Surgery for Persistent Cushing’s Disease
by: Dan Nicolae PADURARU, et al.
Published: (2019-12-01)

The place of medical treatment of acromegaly in Serbia: Current status
by: Doknić Mirjana, et al.
Published: (2021-01-01)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
by: Richard A. Feelders, et al.
Published: (2023-10-01)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
by: Leandro Kasuki, et al.
Published: (2016-10-01)

Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
by: I. A. Ilovayskaya
Published: (2022-06-01)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
by: Cecilia Follin, et al.
Published: (2016-08-01)

Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide
by: Kevin Doello, et al.
Published: (2024-06-01)

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature
by: Hasan Husni, et al.
Published: (2022-03-01)

Acromegaly and the information gap: patient perceptions of the journey from primary to tertiary care
by: Hei Yi Vivian Pak, et al.
Published: (2020-10-01)

Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide
by: Tiffany P Quock, et al.
Published: (2025-07-01)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
by: Sandrine Oziel-Taieb, et al.
Published: (2022-04-01)

A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation
by: Chunying Ma, et al.
Published: (2019-06-01)

Acromegaly and Colorectal Neoplasm: An Update
by: Leandro Kasuki, et al.
Published: (2022-06-01)

Pituitary gigantism due to a novel AIP germline splice-site variant
by: Elisa Lamback, et al.
Published: (2024-10-01)

Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment
by: Junichiro SATO, et al.
Published: (2025-03-01)

Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
by: R. Gostelow, et al.
Published: (2017-03-01)

Changes in acromegaly comorbidities, treatment, and outcome over three decades: a nationwide cohort study
by: Christian Rosendal, et al.
Published: (2024-04-01)

Duhok acromegaly; a prospective cohort study
by: Bayar Ahmed Qasim
Published: (2023-03-01)